Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Change in Account Payables (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Change in Account Payables for 6 consecutive years, with -$5.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables fell 615.46% to -$5.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.0 million, a 251.0% decrease, with the full-year FY2025 number at -$3.0 million, down 251.0% from a year prior.
  • Change in Account Payables was -$5.1 million for Q4 2025 at TScan Therapeutics, down from $1.9 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.9 million in Q3 2025 to a low of -$5.1 million in Q4 2025.
  • A 5-year average of -$26550.0 and a median of $402000.0 in 2022 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: tumbled 4496.43% in 2021, then skyrocketed 475.46% in 2024.
  • TScan Therapeutics' Change in Account Payables stood at -$2.5 million in 2021, then soared by 116.82% to $414000.0 in 2022, then plummeted by 254.83% to -$641000.0 in 2023, then soared by 253.35% to $983000.0 in 2024, then crashed by 615.46% to -$5.1 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Change in Account Payables are -$5.1 million (Q4 2025), $1.9 million (Q3 2025), and -$435000.0 (Q2 2025).